Barbiotis is strengthening its CSR efforts by participating in the United Nations Global Compact and applying the ISO 26000 standard.

La Rochelle, France – (BUSINESS WIRE) – Regulatory News:

Valbiotis (Paris: ALVAL) (FR0013254851 – ALVAL, PEA / PME Eligible) is a R & D company dedicated to scientific innovation to prevent and combat metabolic and cardiovascular diseases and corporate social responsibility (CSR). ) Is being strengthened. ) Participate in the United Nations Global Compact and apply the ISO 26000 standard.

The United Nations Global Compact brings together ten globally recognized principles to bring together businesses, organizations, UN agencies, the world of work and civil society to build a more stable and inclusive society. The Global Compact, a platform framework for voluntary commitment, international reference, action and exchange, is the largest global initiative in terms of social responsibility, with more than 19,000 participants in 170 countries.

Through its membership, Barbiotis supports the ten principles of the United Nations Global Compact on respect for human rights, international labor standards, environmental protection and the fight against corruption.

Through this new initiative, Valbiotis expresses its desire to strengthen these principles, integrate them into long-term strategy, culture and day-to-day operations, and move them forward in influential areas. Barbiotis will also participate in projects that promote the United Nations’ broader development goals, specifically helping to achieve the Sustainable Development Goals (SDGs).

Valbiotis has SDG3 “Health and Welfare” and SDG9 “Industry” by developing innovative plant-derived active substances that prevent metabolic and cardiovascular diseases and act on early state pathologies. , Innovation, Infrastructure ”.

In the first year of the Global Compact membership, Barbiotis promises to take action specifically on the following principles:

– Establish a CSR Steering Committee directly attached to the CEO of Valbiotis, build an ISO 26000 compliant approach, and implement CSR governance with awareness of all employee challenges.

– Assessment of the environmental impact of its activities and implementation of concrete actions to contribute to SDG 13 – Measures related to the fight against climate change.

Sébastien Peltier, CEO and Chairman of the Board comment “By participating in the United Nations Global Compact, which marks a new stage in the company’s growth and development beyond its public health mission, with a focus on reducing the potential effects of metabolic and cardiovascular disease. We are very proud to strengthen our commitment. Millions of people around the world are at risk. This is our priority action area for corporate social responsibility strategies. Reflects the company’s ambition in a new dimension to integrate into our strengths of commitment and objectives. We build a CSR approach that complies with the ISO 26000 standard and are proactive with people and the planet. We aim to get a long-term label in order to continue to grow while acting on. “

At the same time, two years ago, Valbiotis integrated Gaïa-Index, a French benchmark index for Small & MidCaps on ESG, a subsidiary of EthiFinance and a player with ESG (Environment, Social and Governance) ratings. ETI.

Gaïa Research evaluates companies in four pillars: environment, society, governance and external stakeholders (ESG-PPE), according to a benchmark of about 170 standards in France. These criteria make it possible to assess sustainable development and consideration of long-term issues in economic players’ strategies and measure their progress.

About Barbiotis

Valbiotis is a research and development company committed to scientific innovation to prevent and combat metabolic diseases that meet unmet medical needs.

Valbiotis takes an innovative approach and develops a new class of health nutrition products designed to reduce the risk of major metabolic diseases based on a multi-target approach enabled by the use of terrestrial and marine plants. By doing so, we aim to revolutionize health.

The product is intended to be licensed to players in the world of health.

Founded in La Rochel in early 2014, the company has built numerous partnerships with the best academic centers. The company has established three sites in France, Perigny, La Rochelle (17) and Lion (63), and has a subsidiary in Quebec (Canada).

Valbiotis, a member of the “BPI Excellence” network and benefiting from the BPI “Innovative Company” label, also has the status of “Young Innovative Company” and has been awarded the European Regional Economic Development Fund for research programs. We have received a great deal of financial support from the European Union. (ERDF). Valbiotis is a company covered by PEA-PME.

For more information on Valbiotis, please visit www.valbiotis.com.

Name: Barbiotis

ISIN code: FR0013254851

Mnemonic code: ALVAL

EnterNext © PEA-PME150

This press release contains forward-looking statements regarding the purpose of Valbiotis. Valbiotis believes that these predictions are based on the information and reasonable assumptions that Valbiotis currently has. However, these do not guarantee future performance and are questioned by a certain number of risks and uncertainties, including those described in economic conditions, changes in financial markets, and approved Valbiotis Universal Registration Documents. It may be seen. Autorité des marchés financiers (AMF), July 27, 2021 (filing number R 21-039). This document is available on our website (www.valbiotis.com).

This press release and the information contained therein do not constitute an offer to sell or subscribe to Valbiotis shares or financial securities, or to solicit purchase or subscription orders in any country.

contact address

Corporate Communication / Barbiotis

Carol Roche / Mark Deloney

+33 5 46 28 62 58

[email protected]

Media Relations / PrPa

Damian Maillard

+33 6 80 28 47 70

[email protected]

Financial Communication / Actifin

Stephan lewies

+33 1 56 88 11 14

[email protected]